

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

Allergan, Inc.,
Allergan Pharmaceuticals Ireland
Unlimited Company, and Allergan USA, Inc.,

Plaintiffs,

v.

Revance Therapeutics, Inc. and Ajinomoto
Althea, Inc. d/b/a Ajinomoto Bio-Pharma Services,

Defendants.

C.A. No. 21-1411-RGA

PUBLIC VERSION*

**Confidential Version Filed: December 28, 2022
Public Version Filed: January 11, 2023**

**PLAINTIFFS' UNOPPOSED MOTION FOR
LEAVE TO FILE SECOND AMENDED COMPLAINT**

Plaintiffs Allergan, Inc., Allergan Pharmaceuticals Ireland Unlimited Company, and Allergan USA, Inc. (“Allergan” or “Plaintiffs”) respectfully move the Court for leave to amend their First Amended Complaint (D.I. 16) pursuant to the Federal Rule of Civil Procedure 15(a). A copy of the proposed Second Amended Complaint is attached as Exhibit A and a blackline comparing the proposed Second Amended Complaint to the First Amended Complaint is attached as Exhibit B.

Pursuant to D. Del. LR 7.1.1, counsel for Allergan conferred with counsel for Defendants, and Defendants do not oppose Allergan’s motion.

* * *

** Defendants respectfully request that Exhibit 18, which is a portion of their Biologics License Application, remain redacted in its entirety for the same reasons as set forth in their prior motion to seal granted by the Court (D.I. 76, 78).*

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Jeremy A. Tigan

OF COUNSEL:

Eric W. Dittmann
Chad J. Peterman
Melanie R. Rupert
Bruce M. Wexler
Ashley N. Mays-Williams, Ph.D.
Krystina L. Ho, Ph.D.
Carl J. Minniti, III
Amanda E. Hoffman, Ph.D.
PAUL HASTINGS LLP
200 Park Avenue
New York, NY 10166
(212) 318-6000

Jack B. Blumenfeld (#1014)
Jeremy A. Tigan (#5239)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899-1347
(302) 658-9200
jblumenfeld@morrisnichols.com
jtigan@morrisnichols.com

*Attorneys for Plaintiffs Allergan, Inc.,
Allergan Pharmaceuticals Ireland Unlimited
Company, and Allergan USA, Inc.*

December 28, 2022

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

Allergan, Inc.,
Allergan Pharmaceuticals Ireland
Unlimited Company, and Allergan USA, Inc.,

Plaintiffs,

v.

Revance Therapeutics, Inc. and Ajinomoto
Althea, Inc. d/b/a Ajinomoto Bio-Pharma Services,

Defendants.

C.A. No. 21-1411-RGA

[PROPOSED] ORDER

Having considered Plaintiffs' Unopposed Motion for Leave to File Second Amended Complaint (the "Motion"),

IT IS HEREBY ORDERED this ____ day of _____, 20____, that the Motion is GRANTED.

The Honorable Richard G. Andrews
United States District Judge

CERTIFICATE OF SERVICE

I hereby certify that on December 28, 2022, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on December 28, 2022, upon the following in the manner indicated:

Anne Shea Gaza, Esquire
Samantha G. Wilson, Esquire
YOUNG CONAWAY STARGATT
& TAYLOR, LLP
Rodney Square
1000 North King Street
Wilmington, DE 19801
*Attorneys for Defendants Revance Therapeutics,
Inc. and Ajinomoto Althea, Inc. d/b/a Ajinomoto
Bio-Pharma Services*

VIA ELECTRONIC MAIL

Dennies Varughese, Pharm. D.
Eldora L. Ellison, Ph.D.
Adam C. LaRock, Esquire
Olga A. Partington, Ph.D.
Ryan E. Conkin, Esquire
Anna G. Phillips, Esquire
STERNE, KESSLER, GOLDSTEIN
& FOX P.L.L.C.
1100 New York Avenue NW, Suite 600
Washington, DC 20005
*Attorneys for Defendants Revance Therapeutics,
Inc. and Ajinomoto Althea, Inc. d/b/a Ajinomoto
Bio-Pharma Services*

VIA ELECTRONIC MAIL

/s/ Jeremy A. Tigan

Jeremy A. Tigan (#5239)